(Total Views: 606)
Posted On: 05/03/2025 3:13:53 PM
Post# of 154633
Do we know yet if our paper is a Late-Breaking Abstract?
If not, based on this ESMO schedule, it seems likely Cytodyn’s leadership chose to submit it as Late-Breaking.
To be able to report 4+ years of survival data. Please compare Cytodyn’s press release dates to this schedule, especially the last one with the 48+ month survival figures.
Cytodyn's last press release:
https://www.cytodyn.com/newsroom/press-releas...ast-cancer
ESMO website:
https://www.esmo.org/meeting-calendar/esmo-br.../abstracts
If not, based on this ESMO schedule, it seems likely Cytodyn’s leadership chose to submit it as Late-Breaking.
To be able to report 4+ years of survival data. Please compare Cytodyn’s press release dates to this schedule, especially the last one with the 48+ month survival figures.
Cytodyn's last press release:
https://www.cytodyn.com/newsroom/press-releas...ast-cancer
Quote:
The Company has also now confirmed survival outcomes in a group of patients with mTNBC and four prior lines of treatment who are alive more than 48 months after receiving leronlimab
ESMO website:
https://www.esmo.org/meeting-calendar/esmo-br.../abstracts
Quote:
Abstract submission deadlines
Deadline
Date and time
Abstracts
Trial in Progress
Intent to submit LBA
Tuesday, 11 February 2025, 21:00 CET (Central European Time)
Late-breaking abstracts (LBA)
Tuesday, 15 April 2025, 21:00 CEST (Central European Summer Time)
A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline 11 February 2025.
(6)
(0)
